Review
Open access
Jul 2026
From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy
It is concluded that the shift from clinical-only diagnostic criteria to a biomarker-enabled molecular framework is the necessary catalyst for developing effective disease-modifying therapies for PSP and related 4R-tauopathies.
Glenn A Harris, Lymor Barnhard, Jennifer L. Brummet et al.
· Frontiers in Neuroscience · 0 citations